Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Staten Island, New York. It focuses on developing a new class of small molecule antibiotics to treat difficult-to-treat bacterial infections caused by priority pathogens. The company's proprietary approach targets the DNA polymerase IIIC enzyme to inhibit DNA replication in Gram-positive bacteria.
Acurx is a pre-revenue, clinical-stage biopharmaceutical company with no products approved for commercial sale and has not generated any product revenue to date; accordingly, it has no commercial customers or customer concentration.